Rita Faria covers how cost-effectiveness can inform prioritisation of patients for the treatment of hepatitis C, the cost-effectiveness of CAR-T therapy and requests for bad practice in biostatistics.
Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that… Read More »Chris Sampson’s journal round-up for 5th February 2018
NICE recently completed their appraisal of the hepatitis C drug sofosbuvir. However, as has been reported in the media, NHS England will not be complying with the guidance within the normal time period. The cost of a 24 week… Read More »Sofosbuvir: a fork in the road for NICE?